Proxibarbal

Summary

Proxibarbal (CHEMBL2105233) is an approved small molecule (ATC N05CA22).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CA22
• Chemistry: 226.23 Da · C10H14N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105233
Name	Proxibarbal
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	17336
ATC	N05CA22
Molecular formula	C10H14N2O4
Molecular weight	226.23
InChIKey	VNLMRPAWAMPLNZ-UHFFFAOYSA-N

SMILES: CC(CC1(C(=O)NC(=O)NC1=O)CC=C)O

IUPAC name: 5-(2-hydroxypropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione

Also known as: Axeen, Centralgol, HH-184, Hydroxydial, Ipronal, Proxibarbal, PROXIBARBAL

Patent coverage: 378 distinct patent families (1,025 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,021 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).